Jonathan H. Spadt, CEO of RatnerPrestia, to speak during April 3 Patentability Subcommittee Teleconference

Jonathan H. Spadt, CEO of RatnerPrestia, and member of the Patentability Subcommittee of AIPLA will be discussing the reasoning of Justice Breyer’s opinion in Prometheus during the teleconference on April 3. This is the second teleconference on the patent eligibility of medical method patent claims involving a law of nature, specifically focusing on Mayo Collaborative Services v. Prometheus Laboratories, Inc. of March 20, 2012.

The U.S. Supreme Court recently unanimously held that claims on methods of determining whether drug dosing levels should be increased or decreased based on levels of a metabolite in a patient’s bloodstream were not patent-eligible. Jonathan will focus on the reasoning set forth by the Court and what it may mean for the future of personalized medicine.